Pharma Sector

Indian stock markets ended sharply higher on July 29, 2026, with the Sensex gaining 888.68 points and the Nifty closing at 24,250.20. The rally was driven by sustained buying in IT stocks, positive FII inflows, lower market volatility, and expectations of an unchanged US Federal Reserve interest rate. Infosys led the IT surge, while broad-based gains across FMCG, Metals, Pharma, and Financials boosted overall market sentiment.

Dr. Lal Path Labs shares reached a fresh 52-week high of ₹1,894.90 following strong Q1 FY27 performance, supported by robust revenue growth, higher profitability, improved operating margins, and positive management commentary. The company reported a 28% YoY rise in consolidated net profit, strong volume growth, and improved business momentum, strengthening investor confidence in its long-term growth prospects.

Indian benchmark indices staged a strong recovery on July 27, 2026, ending a five-session losing streak. The Nifty and Sensex gained nearly 1% each, supported by easing US-Iran tensions, a sharp decline in crude oil prices, improved global sentiment, and strong buying in IT, Media, Realty, and Auto stocks. Infosys led the IT rally following leadership transition news and positive brokerage sentiment.

Manipal Health Enterprises IPO will open for subscription from July 29 to July 31, 2026, with a price band of ₹560-590 per share. Here's everything investors need to know, including the latest GMP, financial performance, issue details, and investment outlook.

Sensex and Nifty extended losses for the fifth consecutive session as rising crude oil prices, US-Iran tensions, weak Wall Street cues, and higher bond yields weighed on investor sentiment. IT and Media stocks outperformed, while Auto stocks led the decline.

Dr. Reddy's Laboratories stock fell nearly 7% to a fresh 52-week low of ₹1,101 after reporting disappointing Q1 FY27 earnings. A sharp decline in profit, weaker North America sales, margin compression, Semaglutide API quality issues, and cautious analyst commentary triggered heavy selling in the pharma stock.

Indian stock market extended its losing streak on July 23, 2026, with the Sensex falling 363 points and the Nifty closing below 23,900. Escalating US-Iran tensions, higher crude oil prices, persistent FII selling, and weak global sentiment weighed on markets, while the Auto sector emerged as the lone outperformer.

Cipla reported a weak Q1 FY27 performance with net profit declining 39% year-on-year to ₹789 crore. While the One India business delivered record revenue growth, lower US sales and margin pressure impacted overall profitability, leading to a fall in Cipla shares.

Indian benchmark indices ended sharply lower on July 22, 2026, with Sensex falling 715 points and Nifty closing below the 24,000 mark. Investor sentiment weakened after US President Donald Trump's proposed tariffs on imported generic medicines, escalating US-Iran tensions, rising Brent crude oil prices, a weaker rupee, and heavy selling in banking, pharma and IT stocks. Despite the broader market weakness, Bajaj Auto and Nestlé India gained on the back of strong Q1 FY27 earnings.

Indian benchmark indices extended losses for a second straight session on July 21, 2026, with the Nifty 50 and Sensex ending lower due to escalating US-Iran geopolitical tensions, elevated crude oil prices, and persistent FII outflows. Banking and IT heavyweights weighed on the market, while Chemicals and Cement outperformed, led by UltraTech Cement's strong Q1 FY27 earnings and positive brokerage outlook.